Every GLP-1 product A-S Medication Solutions lists
One row per product NDC, in FDA’s words. Strength is printed as FDA lists it, spacing tidied.
| Product | Product NDC | Form and strength | FDA category | Listed | Packages |
|---|---|---|---|---|---|
| OzempicSemaglutide | 50090-5949 | Injection, Solution · Subcutaneous1.34 mg/mL | Approved productNDA · NDA209637 | Since Sep 30, 2020Certified through Dec 31, 2026 | 1 package
|
| OzempicSemaglutide | 50090-8027 | Injection, Solution · Subcutaneous0.68 mg/mL | Approved productNDA · NDA209637 | Since Oct 7, 2022Certified through Dec 31, 2027 | 1 package
|
| OzempicSemaglutide | 50090-6051 | Injection, Solution · Subcutaneous2.68 mg/mL | Approved productNDA · NDA209637 | Since Apr 25, 2022Certified through Dec 31, 2026 | 1 package
|
| WegovySemaglutide | 50090-5824 | Injection, Solution · Subcutaneous0.25 mg/0.5 mL | Approved productNDA · NDA215256 | Since Jun 5, 2021Certified through Dec 31, 2026 | 1 package
|
| MounjaroTirzepatide | 50090-8021 | Injection, Solution · Subcutaneous10 mg/0.5 mL | Approved productNDA · NDA215866 | Since May 13, 2022Certified through Dec 31, 2027 | 1 package
|
| MounjaroTirzepatide | 50090-8022 | Injection, Solution · Subcutaneous12.5 mg/0.5 mL | Approved productNDA · NDA215866 | Since May 13, 2022Certified through Dec 31, 2027 | 1 package
|
| MounjaroTirzepatide | 50090-8023 | Injection, Solution · Subcutaneous7.5 mg/0.5 mL | Approved productNDA · NDA215866 | Since May 13, 2022Certified through Dec 31, 2027 | 1 package
|
| MounjaroTirzepatide | 50090-8024 | Injection, Solution · Subcutaneous5 mg/0.5 mL | Approved productNDA · NDA215866 | Since May 13, 2022Certified through Dec 31, 2027 | 1 package
|
| MounjaroTirzepatide | 50090-8025 | Injection, Solution · Subcutaneous2.5 mg/0.5 mL | Approved productNDA · NDA215866 | Since May 13, 2022Certified through Dec 31, 2027 | 1 package
|
| MounjaroTirzepatide | 50090-8026 | Injection, Solution · Subcutaneous15 mg/0.5 mL | Approved productNDA · NDA215866 | Since May 13, 2022Certified through Dec 31, 2027 | 1 package
|
| Liraglutide | 50090-7501 | Injection · Subcutaneous6 mg/mL | Approved productNDA AUTHORIZED GENERIC · NDA022341 | Since Jun 24, 2024Certified through Dec 31, 2026 | 1 package
|
| SaxendaLiraglutide | 50090-4257 | Injection, Solution · Subcutaneous6 mg/mL | Approved productNDA · NDA206321 | Since Dec 31, 2014Certified through Dec 31, 2026 | 1 package
|
| VictozaLiraglutide | 50090-2853 | Injection · Subcutaneous6 mg/mL | Approved productNDA · NDA022341 | Since Jan 25, 2010Certified through Dec 31, 2026 | 1 package
|
| VictozaLiraglutide | 50090-4503 | Injection · Subcutaneous6 mg/mL | Approved productNDA · NDA022341 | Since Jan 25, 2010Certified through Dec 31, 2026 | 1 package
|
| TrulicityDulaglutide | 50090-3483 | Injection, Solution · Subcutaneous1.5 mg/0.5 mL | Approved productBLA · BLA125469 | Since Sep 18, 2014Certified through Dec 31, 2026 | 1 package
|
| TrulicityDulaglutide | 50090-3484 | Injection, Solution · Subcutaneous0.75 mg/0.5 mL | Approved productBLA · BLA125469 | Since Sep 18, 2014Certified through Dec 31, 2026 | 1 package
|
| TrulicityDulaglutide | 50090-5467 | Injection, Solution · Subcutaneous3 mg/0.5 mL | Approved productBLA · BLA125469 | Since Sep 3, 2020Certified through Dec 31, 2026 | 1 package
|
| TrulicityDulaglutide | 50090-6453 | Injection, Solution · Subcutaneous0.75 mg/0.5 mL | Approved productBLA · BLA125469 | Since Sep 18, 2014Certified through Dec 31, 2026 | 1 package
|
| TrulicityDulaglutide | 50090-6456 | Injection, Solution · Subcutaneous1.5 mg/0.5 mL | Approved productBLA · BLA125469 | Since Sep 18, 2014Certified through Dec 31, 2026 | 1 package
|
| TrulicityDulaglutide | 50090-6571 | Injection, Solution · Subcutaneous3 mg/0.5 mL | Approved productBLA · BLA125469 | Since Sep 3, 2020Certified through Dec 31, 2026 | 1 package
|
| TrulicityDulaglutide | 50090-7589 | Injection, Solution · Subcutaneous4.5 mg/0.5 mL | Approved productBLA · BLA125469 | Since Sep 3, 2020Certified through Dec 31, 2026 | 1 package
|
The rest of its federal record
Checked against every GLP-1 record we publish from FDA. A recall or shortage counts when FDA printed one of this firm’s NDCs in it; a letter or 503B entry counts when the firm name matches exactly. Similar names are listed apart and not counted.
503B outsourcing facility register
Not on the register under this name.
GLP-1 warning letters
None of the GLP-1 warning letters we hold is addressed to this name.
GLP-1 recalls
No GLP-1 recall in FDA’s enforcement reports matches this firm.
FDA enforcement reports, updated by FDA Sep 23, 2026. Every GLP-1 recall
FDA drug shortage list
None of this firm’s NDCs is on FDA’s GLP-1 shortage entries.
FDA drug shortages ↗, updated by FDA Oct 2, 2026.
What these listings mean, and what they do not
- Approved product. A finished product sold under an approved application (NDA, BLA or ANDA). The approval belongs to the application, which Drugs@FDA lists with its holder; the NDC is only the product's identifier.
A listing is not an approval, and not a quality check. It tells FDA a firm makes, labels or compounds a drug. Whether a product was approved is a question about its application, shown above where there is one. Whether a plant passed inspection is a different record again.
The molecules. Semaglutide is the ingredient in Ozempic, Wegovy, Rybelsus; Tirzepatide is the ingredient in Mounjaro, Zepbound; Liraglutide is the ingredient in Victoza, Saxenda; Dulaglutide is the ingredient in Trulicity.
“Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
“Assignment of an NDC number does not in any way denote FDA approval of the product.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
“A labeler may be a manufacturer, including a repackager or relabeler, or the entity named on the product label.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
“The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
Related records
Other firms listing semaglutide, tirzepatide, liraglutide and dulaglutide
FDA registers on this site
Sources
- FDA NDC directory via openFDA ↗, updated by FDA .
- Application holders: Drugs@FDA, updated by FDA Oct 2, 2026.
- FDA’s National Drug Code Directory page ↗ for the quoted definitions.
- Read by us Oct 4, 2026. Not medical advice; this page describes filings, not products’ safety.